These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats. He M; Zhang Q; Deng C; Wang H; Huang XF Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935 [TBL] [Abstract][Full Text] [Related]
43. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Albaugh VL; Judson JG; She P; Lang CH; Maresca KP; Joyal JL; Lynch CJ Mol Psychiatry; 2011 May; 16(5):569-81. PubMed ID: 20308992 [TBL] [Abstract][Full Text] [Related]
44. Effects of abuse pattern of gestational toluene exposure on metabolism, feeding and body composition. Jarosz PA; Fata E; Bowen SE; Jen KL; Coscina DV Physiol Behav; 2008 Mar; 93(4-5):984-93. PubMed ID: 18272189 [TBL] [Abstract][Full Text] [Related]
45. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Patil BM; Kulkarni NM; Unger BS Eur J Pharmacol; 2006 Dec; 551(1-3):112-5. PubMed ID: 17046744 [TBL] [Abstract][Full Text] [Related]
46. Olanzapine affects locomotor activity and meal size in male rats. van der Zwaal EM; Luijendijk MC; Evers SS; la Fleur SE; Adan RA Pharmacol Biochem Behav; 2010 Nov; 97(1):130-7. PubMed ID: 20478328 [TBL] [Abstract][Full Text] [Related]
47. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Raskind MA; Burke BL; Crites NJ; Tapp AM; Rasmussen DD Neuropsychopharmacology; 2007 Feb; 32(2):284-8. PubMed ID: 16710316 [TBL] [Abstract][Full Text] [Related]
48. Effect of chronic intravenous injection of steroid hormones on body weight and composition of female rats. Lobo MJ; Remesar X; Alemany M Biochem Mol Biol Int; 1993 Feb; 29(2):349-58. PubMed ID: 8495217 [TBL] [Abstract][Full Text] [Related]
49. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Kirk SL; Neill JC; Jones DN; Reynolds GP Eur J Pharmacol; 2004 Nov; 505(1-3):253-4. PubMed ID: 15556160 [TBL] [Abstract][Full Text] [Related]
50. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment. Skrede S; Fernø J; Bjørndal B; Brede WR; Bohov P; Berge RK; Steen VM PLoS One; 2012; 7(11):e50853. PubMed ID: 23226405 [TBL] [Abstract][Full Text] [Related]
51. Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Baptista T; de Baptista EA; Lalonde J; Plamondon J; Kin NM; Beaulieu S; Joober R; Richard D Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1305-11. PubMed ID: 15588757 [TBL] [Abstract][Full Text] [Related]
52. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889 [TBL] [Abstract][Full Text] [Related]
54. Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Guesdon B; Denis RG; Richard D Behav Brain Res; 2010 Feb; 207(1):14-20. PubMed ID: 19788900 [TBL] [Abstract][Full Text] [Related]
55. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Karagianis J; Grossman L; Landry J; Reed VA; de Haan L; Maguire GA; Hoffmann VP; Milev R Schizophr Res; 2009 Aug; 113(1):41-8. PubMed ID: 19535229 [TBL] [Abstract][Full Text] [Related]
56. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Davey KJ; O'Mahony SM; Schellekens H; O'Sullivan O; Bienenstock J; Cotter PD; Dinan TG; Cryan JF Psychopharmacology (Berl); 2012 May; 221(1):155-69. PubMed ID: 22234378 [TBL] [Abstract][Full Text] [Related]
57. Chronic intracerebroventricular administration of recombinant CART(42-89) peptide inhibits and causes weight loss in lean and obese Zucker (fa/fa) rats. Larsen PJ; Vrang N; Petersen PC; Kristensen P Obes Res; 2000 Nov; 8(8):590-6. PubMed ID: 11156435 [TBL] [Abstract][Full Text] [Related]
58. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Weston-Green K; Huang XF; Deng C Behav Brain Res; 2011 Mar; 217(2):337-46. PubMed ID: 21056063 [TBL] [Abstract][Full Text] [Related]
59. The effect of ziprasidone on body weight and energy expenditure in female rats. Park S; Kim MS; Namkoong C; Park MH; Hong JP Metabolism; 2012 Jun; 61(6):787-93. PubMed ID: 22209671 [TBL] [Abstract][Full Text] [Related]
60. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. Deng C; Lian J; Pai N; Huang XF J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]